Outcomes for the elderly (≥70 years) from a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC)

Rafat Ansari,Martin J. Edelman,Chandra P. Belani,M. A. Socinski,Coleman K. Obasaju,Matthew J. Monberg,Ruqin Chen,Joseph Treat

Outcomes for the elderly (≥70 years) from a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC)

2009

Rafat Ansari
Martin J. Edelman
Chandra P. Belani
M. A. Socinski
Coleman K. Obasaju
Matthew J. Monberg
Ruqin Chen
Joseph Treat

8052 Background: Approximately 50% of lung cancer patients (pts) are ≥ 70 y, however, this population has been historically underrepresented in clinical trials. Even among pts ≥ 70 y, doublet chemo...

Keywords:

Medicine
Paclitaxel
non-small cell lung cancer (NSCLC)
Oncology
Carboplatin
Gemcitabine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations